ONCAlert | Upfront Therapy for mRCC

Melanoma VIEW MORE >>

In a recent review of the 5-year outcomes from the COMBI-d and COMBI-v trials published in the New England Journal of Medicine, investigators saw long-term benefit with the use of dabrafenib plus trametinib as first-line treatment in about one-third of patients with unresectable or metastatic melanoma and BRAF V600E or V600K mutations.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.